Verification evidence is still being completed.
PDF / print export
Genmab A/S
Copenhagen, Denmark
- Verified lead
- Jan van de Winkel
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- President and Chief Executive Officer
- 2026 technical specialization
- Antibody Therapeutics
- Review cycle
- May 2026
- Full address
- Carl Jacobsens Vej 30, 2500 Valby, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Genmab investor relations source naming Jan van de Winkel as President and CEO.
- Editorial note
- Antibody-engineering anchor with proprietary platform science, late-stage oncology assets, and high-value biologics development capacity.
Antibody Therapeutics
GMP Certified
Antibody-engineering anchor with proprietary platform science, late-stage oncology assets, and high-value biologics development capacity.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Copenhagen, Denmark
Genmab A/S
Antibody Therapeutics · Global Biopharma
Verified 14 Mar 2026 · 3 sources
Biologics
Antibody-engineering anchor with proprietary platform science, late-stage oncology assets, and high-value biologics development capacity.
Contact & location
- Website
- genmab.com
- Company page
- Lead
- Jan van de Winkel (verified ↗)
- Compliance
- GMP Certified
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Global Biopharma
- Capabilities
- DuoBody Platform · HexaBody Platform · Next-gen Antibodies
- Founded
- 1999
- Headcount
- 1001-5000
Clinical profileSTATUS: VERIFIED MARCH 2026
Jan van de Winkel
President and Chief Executive Officer
Full addressCarl Jacobsens Vej 30, 2500 Valby, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Genmab 2024 annual report naming Carl Jacobsens Vej 30, Valby as the corporate address.
Open sourceGlobal Biopharma
Copenhagen, Denmark. Antibody Therapeutics. Review completed on 14 Mar 2026.
DKMA
GMP Certified
Antibody Therapeutics
Antibody-engineering anchor with proprietary platform science, late-stage oncology assets, and high-value biologics development capacity.
Editorial note
Genmab remains a verified benchmark antibody node with Jan van de Winkel leading the executive layer in current company disclosures.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
DuoBody Platform
HexaBody Platform
Next-gen Antibodies
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Robotic Phage Display
Assay Automation
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Genmab A/S located?
- Genmab A/S operates from Carl Jacobsens Vej 30, 2500 Valby, Denmark, Copenhagen, Denmark.
- Who runs Genmab A/S?
- Genmab A/S is led by Jan van de Winkel, President and Chief Executive Officer. Verified 14 Mar 2026.
- What certifications does Genmab A/S hold?
- Genmab A/S is documented under GMP Certified.
- What does Genmab A/S do?
- Antibody-engineering anchor with proprietary platform science, late-stage oncology assets, and high-value biologics development capacity. Core capabilities: DuoBody Platform, HexaBody Platform, Next-gen Antibodies.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.